Genprex Reports Positive Clinical Trial Progress for Reqorsa Gene Therapy and New Biomarker Research Agreement
Summary
Genprex announced a new Sponsored Research Agreement with MD Anderson Cancer Center to study biomarkers for its Reqorsa Gene Therapy, alongside reporting positive safety and early efficacy data from its Acclaim-1 and Acclaim-3 clinical trials for lung cancer.
Key Events
-
New Sponsored Research Agreement
Genprex entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers (TROP2 and PTEN) that may predict patient response to Reqorsa® Gene Therapy for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This extends a long-standing collaboration.
-
Acclaim-1 Clinical Trial Update
The Phase 1/2 clinical trial (Acclaim-1) for NSCLC, combining Reqorsa® with Tagrisso®, showed Reqorsa® was generally well-tolerated with no dose-limiting toxicities. Early efficacy signals included prolonged progression-free survival in some patients, with one patient maintaining a partial response for approximately 42 months.
-
Acclaim-3 Clinical Trial Update
The Phase 1/2 clinical trial (Acclaim-3) for SCLC, combining Reqorsa® with Tecentriq®, also showed no dose-limiting toxicities. One patient achieved an unconfirmed partial remission after 24 cycles of therapy and continues treatment after more than 18 months.
Analysis
This filing provides crucial positive updates for Genprex, a micro-cap biotech company currently facing a potential Nasdaq delisting and seeking shareholder approval for a reverse stock split (as per the PRE 14A filed on 2026-04-17). The new Sponsored Research Agreement with MD Anderson Cancer Center, a long-standing partner, focuses on identifying biomarkers to optimize patient selection for Reqorsa® Gene Therapy in lung cancer. More significantly, the company reported encouraging safety and early efficacy signals from its ongoing Phase 1/2 Acclaim-1 and Acclaim-3 clinical trials, including prolonged progression-free survival and partial responses in some patients. These clinical advancements, particularly the long-term response in one Acclaim-1 patient (42 months), are vital for demonstrating the potential of their lead drug candidate and could help bolster investor confidence as the company navigates its financial and listing challenges.
At the time of this filing, GNPX was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $1.15 to $55.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.